HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.

Abstract
Troglitazone is effective in approximately 50% in patients with type 2 diabetes (NIDDM). In this study, we investigated the relations between serum leptin levels and clinical efficacy of troglitazone. Forty-five type 2 diabetic patients (23 men and 22 women) from our outpatient clinic were treated with troglitazone 400 mg daily for 12 weeks. Fasting plasma glucose (FPG), HbA1c, body weight, serum insulin and leptin concentrations were measured before and after troglitazone treatment. After 12 weeks of troglitazone treatment, FPG (before versus after, 179+/-33 vs. 138+/-26 mg/dl, mean+/-SD), HbA1c (7.8+/-1.3 vs. 6.9+/-1.0%), IRI (8.3+/-4.3 vs. 6.3+/-3.4 microU/ml) and HOMA-R index (homeostasis model assessment of insulin resistance) (3.8+/-2.4 vs. 2.2+/-1.3) decreased significantly, while body mass index (BMI) slightly increased (26.3+/-3.5 vs. 26.6+/- 3.6 kg/m(2)), and serum leptin remained unchanged (8.5+/-7.2 vs. 9.1+/-8.7 ng/ml). Reduction in FPG (DeltaFPG) after troglitazone treatment were correlated with reduction in HOMA-R (DeltaHOMA-R) (r=0.721, P<0.0001). DeltaFPG was correlated with serum leptin (r=0.441, P<0.01), HOMA-R (r=0.460, P<0.01) and FPG (r=-0.781, P<0.0001) at baseline, but not with BMI and serum IRI at baseline. Furthermore, serum leptin at baseline was significantly correlated with DeltaHOMA-R (r=0.634, P<0.01). Leptin concentration before treatment therefore, can be used as an predictor for clinical efficacy of troglitazone in patients with type 2 diabetes.
AuthorsS Maruyama, K Yanagisawa, R Kanamuro, S Teno, Y Iwamoto
JournalDiabetes research and clinical practice (Diabetes Res Clin Pract) Vol. 53 Issue 3 Pg. 161-4 (Sep 2001) ISSN: 0168-8227 [Print] Ireland
PMID11483231 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers
  • Blood Glucose
  • Chromans
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Leptin
  • Thiazoles
  • Thiazolidinediones
  • Troglitazone
Topics
  • Biomarkers (blood)
  • Blood Glucose (analysis)
  • Chromans (therapeutic use)
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Fasting
  • Female
  • Glycated Hemoglobin (analysis)
  • Homeostasis
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Insulin (blood)
  • Insulin Resistance
  • Leptin (blood)
  • Male
  • Middle Aged
  • Models, Biological
  • Predictive Value of Tests
  • Regression Analysis
  • Thiazoles (therapeutic use)
  • Thiazolidinediones
  • Time Factors
  • Troglitazone

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: